GCICreo device used in 'groundbreaking' lung cancer procedure
announced a significant milestone in the field of minimally-invasive surgical endoscopy for cancer patients on Friday, with its 'MicroBlate Flex' device.
The AIM-traded company announced that professor Pallav Shah and Dr Christopher Orton, specialists from the Royal Brompton Hospital, had successfully conducted the world's first robotic-guided microwave ablation of lung tissue concurrently with a diagnostic procedure.
It said the pioneering procedure, using its MicroBlate Flex device, targeted a 27mm cancerous nodule within a patient's lung.
The achievement was considered a notable advancement in the medical community's ability to diagnose, stage, and treat lung cancer in a single sitting.
In a statement, Dr Orton emphasised the potential of the innovative approach, saying the "potential to combine the diagnosis, staging, and treatment of lung cancer in one procedure offers significant benefit to patients".
Creo said the procedure, conducted at the Royal Brompton Hospital in London, reportedly lasted just three minutes.
"Creo has been pioneering minimally invasive surgical endoscopy for pre-cancer and cancer patients for years, and implementing our technology into robotic application is a key goal for us as the adoption of this technology continues to grow exponentially," said chief executive officer Craig Gulliford.
"We are incredibly proud that our MicroBlate Flex technology has been able to make this world-first possible.
"The potential for these technologies to combine precise robotically guided lung cancer diagnosis with the ablation of cancerous tissue in one session is transformational."
Gulliford said that could "dramatically improve" outcomes for lung cancer patients, and had the potential to remove "long and worrying" delays between diagnosis and treatment.
"This is the beginning of an exciting programme and the team have done a terrific job in reaching this point."
At 1411 GMT, shares in Creo Medical Group were up 0.84% at 30p.
Reporting by Josh White for Sharecast.com.
Disclaimer & Declaration of Interest
The information, investment views and recommendations in this article are provided for general information purposes only. Nothing in this article should be construed as a solicitation to buy or sell any financial product relating to any companies under discussion or to engage in or refrain from doing so or engaging in any other transaction. Any opinions or comments are made to the best of the knowledge and belief of the writer but no responsibility is accepted for actions based on such opinions or comments. Vox Markets may receive payment from companies mentioned for enhanced profiling or publication presence. The writer may or may not hold investments in the companies under discussion.